{
    "clinical_study": {
        "@rank": "82337", 
        "arm_group": {
            "arm_group_label": "Aripiprazole", 
            "arm_group_type": "Experimental", 
            "description": "Aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over 52 weeks to subjects who complete the 031-09-003 study"
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to investigate the safety and efficacy of aripiprazole\n      (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally\n      administered over a period of 52 weeks in subjects who complete a short-term treatment study\n      of pediatric patients (aged 13-17 years) with schizophrenia (031-09-003 study)."
        }, 
        "brief_title": "A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60),\n             according to DSM-IV-TR\n\n          -  Male and female patients aged 13-17 years\n\n          -  Patients completing the 031-09-003 study\n\n          -  Patients who, in addition to their legal guardian, provide written informed consent,\n             having understood the details of this study\n\n          -  Inpatient or outpatient status\n\n        Exclusion Criteria:\n\n          -  Patients who have a diagnosis of any other disease except schizophrenia, according to\n             DSM-IV-TR\n\n          -  Patients who have been compulsorily admitted to hospital\n\n          -  Patients with mental retardation\n\n          -  Patients with thyroid disorder\n\n          -  Patients who fall under a contraindication listed in the ABILIFY package insert\n\n          -  Patients with a serious hepatic, renal, cardiac or hematopoietic disorder\n\n          -  Patients with a history or a complication of organic brain disorder or convulsive\n             disorder such as epilepsy\n\n          -  Patients with a history or a complication of diabetes and patients who fall under any\n             of the following: fasting blood glucose level \u2267 126 mg/dL, non-fasting blood glucose\n             level \u2267 200 mg/dL, HbA1c \u2267 6.5%\n\n          -  Patients with a history or a complication of suicide attempt, suicidal thought or\n             self-harm\n\n          -  Patients with a score of \u22672(mild) on PART1 evaluation of CGI-SS\n\n          -  Patients with a history or a complication of malignant syndrome, tardive dyskinesia\n             or paralytic ileus\n\n          -  Patients in a state of physical exhaustion accompanied by such conditions as\n             dehydration or malnutrition\n\n          -  Patients with a history or a complication of water intoxication\n\n          -  Patients with Parkinson's disease\n\n          -  Pregnant women, parturient women, nursing women, women of childbearing potential who\n             wish to become pregnant during this trial.  However, women of childbearing potential\n             who are practicing an appropriate method of contraception (refer to 8.6) and have a\n             negative pregnancy test result are eligible for inclusion in this study.\n\n          -  Study enrollment is otherwise judged to be inappropriate by the Investigator or\n             Subinvestigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942148", 
            "org_study_id": "031-09-004", 
            "secondary_id": "JapicCTI-101147"
        }, 
        "intervention": {
            "arm_group_label": "Aripiprazole", 
            "intervention_name": "Aripiprazole", 
            "intervention_type": "Drug", 
            "other_name": "Abilify"
        }, 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Schizophrenia, Pediatric patients", 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shikoku Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pediatric Patients (Aged 13-17 Years) With Schizophrenia (031-09-003 Study)", 
        "overall_contact": {
            "last_name": "Drug Information Center", 
            "phone": "+81-3-6361-7314"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Kyoji Imaoka, Mr", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942148"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Positive and Negative Syndrome Scale (PANSS)", 
                "safety_issue": "No", 
                "time_frame": "Week1, Week2, Week4, Week8, Week12, Week16, Week24, week32, Week40, Week48, Week52"
            }, 
            {
                "measure": "Clinical golobal impression (CGI)", 
                "safety_issue": "No", 
                "time_frame": "Week1, Week2, Week4, Week8, Week12, Week16, Week24, week32, Week40, Week48, Week52"
            }, 
            {
                "measure": "Children's Global Assessment Scale (CGAS)", 
                "safety_issue": "No", 
                "time_frame": "Week24, Week52"
            }
        ], 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}